Therefore, it is possible that another tumor suppressor function for CYLD may be to activate the RIPK1 death-signaling response, and antagonizing this death pathway by deleting or otherwise inhibiting CYLD would be expected to provide a survival advantage to tumors. This evidence concerns the gene RIPK1 and neoplasm.